Teva introduces generic Cardene injection
IRVINE, Calif. Teva has released the first generic nicardipine hydrochloride injection, the generic drug maker announced Wednesday.
The injection is equivalent to EKR Therapeutics’ blood-pressure drug Cardene and is available in doses of 2.5 mg per milliliter to 25 mg. Cardene had sales of $40.5 million in the second quarter of 2007, according to Forbes.
“Our customers look to us for a continuous supply of new health systems generics,” Teva marketing director Jennifer Guzman said. “Teva’s commitment to new product development assures important new products like nicardipine hydrochloride injection are available on a timely basis.”
Rx Response mobilizes to respond to Hurricane Gustav
WASHINGTON With Hurricane Gustav barely missing New Orleans, several retail pharmacy, pharmaceutical and medical industry organizations have mobilized to respond.
Rx Response’s purpose is to provide a single point of contact between emergency management officials and the pharmaceutical supply system. It uses a network that allows the officials to communicate with it concerning issues that might affect the supply system, such as pharmaceutical needs. For example, public health officials in Louisiana and Alabama have asked it for a list of pharmacies that closed when Gustav made landfall so that they could direct patients to operating pharmacies.
The organization began almost two years ago in response to Hurricane Katrina and the threat of pandemic influenza. Its members include the American Hospital Association, the American Red Cross, the Biotechnology Industry Organization, the Generic Pharmaceutical Association, the Healthcare Distribution Management Association, the National Association of Chain Drug Stores, the National Community Pharmacists Association and the Pharmaceutical Research and Manufacturers of America.
Old anti-itching drug may become new hepatitis treatment
STANFORD, Calif. Researchers at Stanford University have found a possible new way to combat hepatitis C, according to a report published online in the Aug. 31 issue of Nature Biotechnology.
The researchers found that clemizole hydrochloride, an anti-itching drug, hindered a protein in the hepatitis C virus called NS4B, which is crucial to the virus’ replication without harming cells similar to those found in the liver, which the virus targets.
“We’re excited about this, and we’re actively moving forward toward clinical trials,” said Dr. Jeffrey Glenn, an associate professor of gastroenterology and hepatology at Stanford.
Glenn said that if it proves effective in human trials, clemizole could become an essential component in a new class of multi-drug treatments for hepatitis C.